Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes

M Freeman-Keller, Y Kim, H Cronin, A Richards… - Clinical Cancer …, 2016 - AACR
Purpose: Retrospective analysis of irAEs in melanoma patients treated with nivolumab.
Experimental Design: Data were pooled from 148 patients (33 resected, 115 unresectable) …

Pruritus associated with targeted anticancer therapies and their management

J Wu, ME Lacouture - Dermatologic clinics, 2018 - derm.theclinics.com
Aberrations in cell signal transduction pathways, including EGFR, MAPK (RAS-RAF-MEK-
ERK), and PI3K-Akt-mTOR, play an essential role in tumorigenesis and disease …

[HTML][HTML] Guideline-recommended symptom management strategies that cross over two or more cancer symptoms

K Kwekkeboom - Number 5/September 2020, 2020 - onf.ons.org
Problem Identification: Patients with cancer experience multiple symptoms, but current
practice is driven by guidelines that address single symptoms. Identifying symptom …

Immune checkpoint inhibitors in metastatic melanoma therapy

V Shah, V Panchal, A Shah, B Vyas… - Medicine …, 2024 - spandidos-publications.com
An increase in the incidence of melanoma has been observed in recent decades, which
poses a significant challenge due to its poor prognosis in the advanced and metastatic …

Adverse Event Management in Patients with BRAF V600E‐Mutant Non‐Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib

A Chalmers, L Cannon, W Akerley - The Oncologist, 2019 - academic.oup.com
Therapies for advanced non‐small cell lung cancer (NSCLC) continue to become more
sophisticated. Chemotherapeutics are giving way to newer approaches such as immune …

MAPK pathway–targeted therapies: care and management of unique toxicities in patients with advanced melanoma

KM Rubin - Number 6/December 2017, 2017 - ons.org
Background: Agents targeting the MAPK pathway, including inhibitors of BRAF and MEK,
have dramatically transformed the treatment landscape for patients with BRAF-mutant …

Role of nuclear factor erythroid 2-related factor 2 (NRF-2) mediated antioxidant response on the synergistic antitumor effect of L-arginine and 5-fluro uracil (5FU) in …

A Bala, SS Panditharadyula - Current Pharmaceutical Design, 2019 - ingentaconnect.com
Breast adenocarcinoma (BAC) in glandular tissue cells have excessive metastasis and
invasion capability. The major challenges for the chemotherapy used for the management of …

[HTML][HTML] Guideline-Recommended Symptom Management Strategies That Cross Over Two or More Cancer Symptoms

KKAWJ Stevens, LTK Montgomery - Oncology Nursing Forum - ons.org
Problem Identification: Patients with cancer experience multiple symptoms, but current
practice is driven by guidelines that address single symptoms. Identifying symptom …

[PDF][PDF] Zespół erytrodyzestezji dłoniowo-podeszwowej (PPE, ang. palmoplantar erythrodysesthesia) w przebiegu leczenia sunitynibem–opis przypadku

K Sobańska, Z Synowiec… - Farmacja …, 2015 - akademiamedycyny.pl
Zespół erytrodyzestezji dłoniowo-podeszwowej (zespół ręka–stopa) to częste działanie
niepożądane niektórych klasycznych chemioterapeutyków, a także leków celowanych …

[PDF][PDF] ZESPÓŁ ERYTRODYZESTEZJI DŁONIO-WO-PODESZWOWEJ (PALMOPLANTAR ERYTHRODYSESTHESIA) U CHOREGO Z RAKIEM NERKI LECZONEGO …

PPEINA PATIENT - WSPÓŁCZESNEJ MEDYCYNY CZĘŚĆ …, 2023 - wydawnictwo.umed.pl
Zespół erytrodyzestezji dłoniowo-podeszwowej, zwany inaczej zespołem ręka–stopa, może
rozwinąć się jako działanie niepożądane terapii przeciwnowotworowych z zastosowaniem …